Retension Pharma director Franklin M. Berger acquires 10,000 common shares for $120,000

Retension Pharmaceuticals director Franklin M. Berger increased exposure to the stock via conversion into 12,517 common shares. Separate purchase added 10,000 common shares at $12, held indirectly through FMB Research. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Retension Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-109155), on October 13, 2026, and is solely responsible for the information contained therein. (C)